Chi‐An Cheng
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 5%
- Nanoplatforms for cancer theranostics
- Graphene and Nanomaterials Applications
Papers in
-
- SARS-CoV-2 and COVID-19 Research 8
-
- Extracellular vesicles in disease 4
- Advanced biosensing and bioanalysis techniques 3
- Co-authors
- Jeffrey I. Zink (9 shared papers)Wei Chen (8 shared papers)Huan‐Cheng Chang (3 shared papers)Yung Kuo (1 shared paper)John Yu (1 shared paper)Wei-Wei Chang (1 shared paper)Chin-Hsiang Chien (1 shared paper)Yan‐Kai Tzeng (1 shared paper)
- Journals
- RSC Advances (3 papers)Clinical Infectious Diseases (2 papers)Journal of the American Chemical Society (2 papers)Open Forum Infectious Diseases (2 papers)Small (2 papers)
- Partner nations
- United StatesTaiwanChina
In The Last Decade
Chi‐An Cheng
31 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 103
- Biomaterials 296
- Biomedical Engineering 520
- Materials Chemistry 516
- Infectious Diseases 161
- Pharmaceutical Science 30
Countries citing papers authored by Chi‐An Cheng
This map shows the geographic impact of Chi‐An Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi‐An Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi‐An Cheng more than expected).
Fields of papers citing papers by Chi‐An Cheng
This network shows the impact of papers produced by Chi‐An Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi‐An Cheng. The network helps show where Chi‐An Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Chi‐An Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 196 | |
| 2 | 2019 | 170 | |
| 3 | 2021 | 139 | |
| 4 | 2019 | 109 | |
| 5 | 2011 | 106 | |
| 6 | 2019 | 88 | |
| 7 | 2019 | 82 | |
| 8 | 1998 | 80 | |
| 9 | 2018 | 56 | |
| 10 | 2019 | 31 | |
| 11 | 2022 | 26 | |
| 12 | 2021 | 23 | |
| 13 | 2020 | 20 | |
| 14 | 2021 | 19 | |
| 15 | 2018 | 15 | |
| 16 | 2024 | 14 | |
| 17 | 2023 | 9 | |
| 18 | 2022 | 8 | |
| 19 | 2021 | 7 | |
| 20 | 2021 | 6 |
About Chi‐An Cheng
Chi‐An Cheng is a scholar working on Infectious Diseases, Molecular Biology, Materials Chemistry, Biomaterials and Biomedical Engineering, having authored 32 papers that have together received 1.2k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (8 papers), Nanoparticle-Based Drug Delivery (7 papers), MicroRNA in disease regulation (4 papers), Extracellular vesicles in disease (4 papers), Perovskite Materials and Applications (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Advanced biosensing and bioanalysis techniques (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Biomaterials (296 citations), Biomedical Engineering (520 citations), Materials Chemistry (516 citations), Infectious Diseases (161 citations) and Pharmaceutical Science (30 citations). Chi‐An Cheng has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Jeffrey I. Zink, Wei Chen, Huan‐Cheng Chang, Yung Kuo, John Yu, Wei-Wei Chang, Chin-Hsiang Chien, Yan‐Kai Tzeng, Tsai‐Jung Wu and Oliver T. Bruns. Their work appears in journals such as RSC Advances, Clinical Infectious Diseases, Journal of the American Chemical Society, Open Forum Infectious Diseases and Small.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.